Drug intelligence / Profile preview

WecMix01

Development stage: Preclinical
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

WecMix01 is a CRISPR-optimized probiotic consortium consisting of five bacterial strains, including Bifidobacterium animalis WKB148, designed for precision radioprotection and gut microenvironment reprogramming. The consortium is delivered via a pH-gated supramolecular armor composed of Fe³⁺-tannic acid coordination functionalized with hyaluronic acid for CD44 targeting. This biohybrid platform is engineered to protect the intestinal stem cell niche through HDAC3-Notch1 activation, induce IL-22⁺ macrophages to mediate gut-liver crosstalk, and reset the microbial landscape to increase butyrate production. Mechanistically, it exhibits potent reactive oxygen species (ROS) scavenging capabilities and promotes adipocyte browning via PPARγ-UCP1 activation, making it a candidate for treating radiation-induced injury and obesity-associated radiation syndrome.

Targets

TLR4 (Toll-like receptor 4)HDAC3 (Histone Deacetylase 3)UCP1 (Uncoupling protein 1)PPARG (Peroxisome proliferator-activated receptor gamma)NOTCH (Neurogenic locus notch homolog protein 3)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on WecMix01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WecMix01.

Explore the full profile